Indication
As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.
Medicine details
- Medicine name:
- danicopan (Voydeya)
- SMC ID:
- SMC2675
- Pharmaceutical company
- Alexion Pharma UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 13 January 2025
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 04 November 2024